SCHEMBL7563850

SCHEMBL7563850

CS(=O)(=O)Nc1ccc(NC(=O)NC2=CC(=O)SC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 1/20 0.45
PIP4K2B P78356 1/20 0.45
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
XDH P47989 1/20 0.40
RECQL P46063 1/20 0.40
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KEAP1 Q14145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8210609 0.83 RAB9A (0.50) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL7517281 0.81 KMT2A (0.62) MEN1KMT2A
SCHEMBL7518699 0.80 MAOA (0.51) LMNAMEN1KMT2AHTT
SCHEMBL7521962 0.80 ALDH1A1 (0.51) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL7529461 0.80 KMT2A (0.49) KDM4ELMNAMEN1KMT2AHTT
SCHEMBL7524755 0.80 SMN1; SMN2 (0.55) LMNAMEN1KMT2AHTTSMN1; SMN2
SCHEMBL7520625 0.76 PIP4K2A (0.42) PIP4K2APIP4K2BKDM4ELMNAXDH
SCHEMBL14365948 0.74 PIP4K2A (0.70) PIP4K2APIP4K2BKDM4ELMNAHPGD
SCHEMBL7518438 0.74 EPHX1 (0.61) KDM4ELMNAHPGDALDH1A1MEN1
SCHEMBL7525033 0.74 RAB9A (0.56) KDM4EHPGDALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH 2002-05-16 US disclosed
US-6333346-B1 AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 2001-12-25 US disclosed
EP-1009747-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS Roche Diagnostics GmbH (DE) 2000-06-21 EP disclosed
WO-1999012917-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents UTS2R, SRD5A2, SRD5A1 PIP4K2A 2296/4885PIP4K2B 2231/4885KDM4E 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.